6.1.2 Concurrent opioid use or MOUDs
The use of psychedelics as an add-on to, or concurrently with medications that work at the MOR may have unintended effects. Being prepared to prevent or mitigate possible withdrawal states should be taken into consideration. The impact of possible withdrawal states on the subjective psychedelic experience should also be considered and timing of dosing of any concurrent MOR should be thoughtfully considered. For many studies of ibogaine and noribogaine, MOUD is commonly switched to shorter-acting medications such as controlled-release oral morphine products or other short-acting MOR agonists.125 There are also possibly important safety concerns related to concurrent use of opioids and some psychedelics, which are reviewed below.